Disc Medicine (IRON) Expected to Announce Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is projected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Disc Medicine to post earnings of ($1.06) per share for the quarter.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Trading Up 3.0 %

Shares of NASDAQ IRON opened at $52.83 on Wednesday. The stock’s 50-day moving average is $55.77 and its 200 day moving average is $56.04. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $68.86. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -13.27 and a beta of 0.73.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 19,820 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $63.14, for a total value of $1,251,434.80. Following the completion of the sale, the chief executive officer now owns 72,065 shares in the company, valued at $4,550,184.10. This represents a 21.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the completion of the sale, the chief operating officer now owns 40,555 shares of the company’s stock, valued at approximately $2,213,491.90. The trade was a 3.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 346,617 shares of company stock valued at $19,182,953 over the last 90 days. Company insiders own 4.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating on the stock. Scotiabank raised their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. HC Wainwright restated a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley reiterated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Finally, Cantor Fitzgerald lifted their price target on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine has an average rating of “Buy” and an average price target of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.